|
1
|
Nentwich MF, Bockhorn M, König A, Izbicki
JR and Cataldegirmen G: Surgery for advanced and metastatic
pancreatic cancer-current state and trends. Anticancer Res.
32:1999–2002. 2012.PubMed/NCBI
|
|
2
|
Fidler IJ: Origin and biology of cancer
metastasis. Cytometry. 10:673–680. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liotta LA, Steeg PS and Stetler-Stevenson
WG: Cancer metastasis and angiogenesis: An imbalance of positive
and negative regulation. Cell. 64:327–336. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Walsh N, O'Donovan N, Kennedy S, Henry M,
Meleady P, Clynes M and Dowling P: Identification of pancreatic
cancer invasion-related proteins by proteomic analysis. Proteome
Sci. 7:32009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ramer R, Weinzierl U, Schwind B, Brune K
and Hinz B: Ceramide is involved in r(+)-methanandamide-induced
cyclooxygenase-2 expression in human neuroglioma cells. Mol
Pharmacol. 64:1189–1198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mollace V, Muscoli C, Masini E, Cuzzocrea
S and Salvemini D: Modulation of prostaglandin biosynthesis by
nitric oxide and nitric oxide donors. Pharmacol Rev. 57:217–252.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pereira C, Sousa H, Silva J, Brandão C,
Elgueta-Karstegl C, Farrell PJ, Medeiros R and Dinis-Ribeiro M: The
−1195G allele increases the transcriptional activity of
cyclooxygenase-2 gene (COX-2) in colon cancer cell lines. Mol
Carcinog. 53(Suppl 1): E92–E95. 2014. View
Article : Google Scholar
|
|
9
|
Wójcik M, Ramadori P, Blaschke M, Sultan
S, Khan S, Malik IA, Naz N, Martius G, Ramadori G and Schultze FC:
Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue
macrophages in normal rat liver and to recruited mono-nuclear
phagocytes in liver injury and cholangiocarcinoma. Histochem Cell
Biol. 137:217–233. 2012. View Article : Google Scholar
|
|
10
|
Young AL, Chalmers CR, Hawcroft G, Perry
SL, Treanor D, Toogood GJ, Toogood GJ, Jones PF and Hull MA:
Regional differences in prostaglandin E2 metabolism in
human colorectal cancer liver metastases. BMC Cancer. 13:922013.
View Article : Google Scholar
|
|
11
|
Shibata-Kobayashi S, Yamashita H, Okuma K,
Shiraishi K, Igaki H, Ohtomo K and Nakagawa K: Correlation among 16
biological factors [p53, p21(waf1), MIB-1 (Ki-67), p16 (INK4A),
cyclin D1, E-cadherin, Bcl-2, TNF-α, NF-κB, TGF-β, MMP-7, COX-2,
EGFR, HER2/neu, ER and HIF-1α] and clinical outcomes following
curative chemoradiation therapy in 10 patients with esophageal
squamous cell carcinoma. Oncol Lett. 5:903–910. 2013.PubMed/NCBI
|
|
12
|
Yan WF, Sun PC, Nie CF and Wu G:
Cyclooxygenase-2 polymorphisms were associated with the risk of
gastric cancer: Evidence from a meta-analysis based on case-control
studies. Tumour Biol. 34:3323–3330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hillion J, Smail SS, Di Cello F, Belton A,
Shah SN, Huso T, Schuldenfrei A, Nelson DM, Cope L, Campbell N, et
al: The HMGA1-COX-2 axis: A key molecular pathway and potential
target in pancreatic adenocarcinoma. Pancreatology. 12:372–379.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okami J, Nakamori S, Hiraoka N, Tsujie M,
Hayashi N, Yamamoto H, Fujiwara Y, Nagano H, Dono K, Umeshita K, et
al: Suppression of pancreatic cancer cell invasion by a
cycloox-ygenase-2-specific inhibitor. Clin Exp Metastasis.
20:577–584. 2003. View Article : Google Scholar
|
|
15
|
Duan DP, Dang XQ, Wang KZ, Wang YP, Zhang
H and You WL: The cyclooxygenase-2 inhibitor NS-398 inhibits
proliferation and induces apoptosis in human osteosarcoma cells via
downregulation of the survivin pathway. Oncol Rep. 28:1693–1700.
2012.PubMed/NCBI
|
|
16
|
Youns M, Efferth T and Hoheisel JD:
Transcript profiling identifies novel key players mediating the
growth inhibitory effect of NS-398 on human pancreatic cancer
cells. Eur J Pharmacol. 650:170–177. 2011. View Article : Google Scholar
|
|
17
|
Araki E, Forster C, Dubinsky JM, Ross ME
and Iadecola C: Cyclooxygenase-2 inhibitor ns-398 protects neuronal
cultures from lipopolysaccharide-induced neurotoxicity. Stroke.
32:2370–2375. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kumar S, Boehm J and Lee JC: p38 MAP
kinases: Key signalling molecules as therapeutic targets for
inflammatory diseases. Nat Rev Drug Discov. 2:717–726. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen X, Lin J, Kanekura T, Su J, Lin W,
Xie H, Wu Y, Li J, Chen M and Chang J: A small interfering
CD147-targeting RNA inhibited the proliferation, invasiveness and
metastatic activity of malignant melanoma. Cancer Res.
66:11323–11330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshida S, Ujiki M, Ding XZ, Pelham C,
Talamonti MS, Bell RH Jr, Denham W and Adrian TE: Pancreatic
stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and
pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer. 4:272005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yip-Schneider MT, Barnard DS, Billings SD,
Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS
and Sweeney CJ: Cyclooxygenase-2 expression in human pancreatic
adenocarcinomas. Carcinogenesis. 21:139–146. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Molina MA, Sitja-Arnau M, Lemoine MG,
Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression
in human pancreatic carcinomas and cell lines: Growth inhibition by
nonsteroidal anti-inflammatory drugs. Cancer Res. 59:4356–4362.
1999.PubMed/NCBI
|
|
23
|
Tucker ON, Dannenberg AJ, Yang EK, Zhang
F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT
and Fahey TJ III: Cyclooxygenase-2 expression is up-regulated in
human pancreatic cancer. Cancer Res. 59:987–990. 1999.PubMed/NCBI
|
|
24
|
Wang X, Liang Y, Wang J and Wang M: Effect
of NS-398, a cyclooxygenase-2 selective inhibitor, on the
cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells.
Tumour Biol. 34:1517–1522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Honjo S, Osaki M, Ardyanto TD, Hiramatsu
T, Maeta N and Ito H: COX-2 inhibitor, NS398, enhances Fas-mediated
apoptosis via modulation of the PTEN-Akt pathway in human gastric
carcinoma cell lines. DNA Cell Biol. 24:141–147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Banu N, Buda A, Chell S, Elder D, Moorghen
M, Paraskeva C, Qualtrough D and Pignatelli M: Inhibition of COX-2
with NS-398 decreases colon cancer cell motility through blocking
epidermal growth factor receptor transactivation: Possibilities for
combination therapy. Cell Prolif. 40:768–779. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Elder DJ, Halton DE, Playle LC and
Paraskeva C: The MEK/ERK pathway mediates COX-2-selective
NSAID-induced apoptosis and induced COX-2 protein expression in
colorectal carcinoma cells. Int J Cancer. 99:323–327. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yurchenko V, Constant S and Bukrinsky M:
Dealing with the family: CD147 interactions with cyclophilins.
Immunology. 117:301–309. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yurchenko V, Constant S, Eisenmesser E and
Bukrinsky M: Cyclophilin-CD147 interactions: A new target for
anti-inflammatory therapeutics. Clin Exp Immunol. 160:305–317.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gabison EE, Hoang-Xuan T, Mauviel A and
Menashi S: EMMPRIN/CD147, an MMP modulator in cancer, development
and tissue repair. Biochimie. 87:361–368. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang Y, Lu N, Zhou J, Chen ZN and Zhu P:
Cyclophilin A up-regulates MMP-9 expression and adhesion of
monocytes/macrophages via CD147 signalling pathway in rheumatoid
arthritis. Rheumatology (Oxford). 47:1299–1310. 2008. View Article : Google Scholar
|
|
32
|
Tang Y, Nakada MT, Rafferty P, Laraio J,
McCabe FL, Millar H, Cunningham M, Snyder LA, Bugelski P and Yan L:
Regulation of vascular endothelial growth factor expression by
EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res.
4:371–377. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nabeshima K, Iwasaki H, Koga K, Hojo H,
Suzumiya J and Kikuchi M: Emmprin (basigin/CD147): Matrix
metalloproteinase modulator and multifunctional cell recognition
molecule that plays a critical role in cancer progression. Pathol
Int. 56:359–367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun J and Hemler ME: Regulation of MMP-1
and MMP-2 production through CD147/extracellular matrix
metalloproteinase inducer interactions. Cancer Res. 61:2276–2281.
2001.PubMed/NCBI
|
|
35
|
Kanekura T, Chen X and Kanzaki T: Basigin
(CD147) is expressed on melanoma cells and induces tumor cell
invasion by stimulating production of matrix metalloproteinases by
fibroblasts. Int J Cancer. 99:520–528. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kolli-Bouhafs K, Boukhari A, Abusnina A,
Velot E, Gies JP, Lugnier C and Rondé P: Thymoquinone reduces
migration and invasion of human glioblastoma cells associated with
FAK, MMP-2 and MMP-9 downregulation. Invest New Drugs.
30:2121–2131. 2012. View Article : Google Scholar
|
